BPE Festival - Bordeaux PharmacoEpi

BPE has created a very high scientific level Festival dedicated to pharmacoepidemiology: the Bordeaux PharmacoEpi Festival, which is organized since 2010 (eight editions of the Festival have been held to date)
Over three days, six world-class experts come to Bordeaux to talk of the topic of their choice, each for half a day.
This original master class format allows the BPE team and also all participants to be in the front line on the major news of the discipline as well as on its hot topics.

Edition 2020

Due to the COVID-19 pandemic, we decided
to reprogram next year the 9^th Bordeaux PharmacoEpi Festival
in May 2021.
(originally scheduled for May 25 to 27, 2020)

We apologise for this postponement.
The safety of our participants is our top priority.
We will keep you informed of the new dates as soon as possible.
Thank you for your understanding.

2019 edition
	Catherine Quantin Dijon	The validity of diagnoses in public health databases (with invited speakers)
	Tania Schink Bremen, Germany	Internal validation of outcomes in public health databases
	Giuseppe Traversa Rome, Italy	Governing pharmaceutical care: Do we need to worry about the "excessive" prices of drugs? A pharmacoepidemiologist perspective
	Gianluca Trifiró Messine, Italy	Challenges in postmarketing surveillance of biologics in the era of biosimilars
	Bernard Bégaud Bordeaux	[General Public Conference] A quoi peut servir la pharmacoépidémiologie ?
	Kristian B. Filion Montreal, Canada	The safety of antidiabetic drugs, and Distributed Drug Safety Networks/CNODES
	Ron Herings Amsterdam, NL	Scenario and prediction modeling In pharmacoepidemiology for health personalization
2018 edition
	Munir Pirmohammed Liverpool, UK	The excitement and challenges of being a clinical pharmacologist
	Jacques Le Lorier Quebec, CA	The Pharmacologically Pertinent Period of Effect. Are the editors doing their job ?
	Susana Perez-Gutthann Barcelona	Looking behind the code
	Corinne de Vries London, UK	Drug safety in pregnancy
	Tom Walley Liverpool, UK	Clinical research in the UK
	John Ioannidis Stanford, USA	Reproducible and useful epidemiology: why and how
2017 edition
	Andy Stergachis Seattle, USA	How to communicate benefits and risks, based on pharmacoepidemiological studies
	Jesper Hallas Odense - Denmark	Pharmacovigilance in low- and middle-income countries: need, issues, methods, case studies, and future directions.
	Gerard de Pouvourville Paris	Pharmacoeconomics in the modern world.
	Til Stürmer North Carolina, USA	Principled versus pragmatic pharmacoepidemiology: do we need to take sides?
	Jaime Caro Boston, USA	The use of DICE simulation for epidemiologic models
	Marc Rodwin Boston, USA	1) How can inappropriate off-label drug use be managed? 2) Financial relations between pharmaceutical firms and physicians
2015 edition
	Arnold Chan Taipei, Taiwan	Pharmacoepidemiology and drug safety in Asia.
	Jerry Avorn Boston, USA	Patients, doctors and drug safety
	Sonia Hernandez-Diaz Boston, USA	Are babies the only outcomes in pregnancy?
	Stella Blackburn London, UK	Considerations on risk-benefit assessment
	Bert Leufkens Utrecht, NL	Pharmacovigilance is here to stay
2014 edition
	Saad Shakir Boston, USA	Risk Management in Pharmacovigilance: what is under the bonnet?
	Joshua Gagne Boston, USA	Disease risk scores in pharmacoepidemiology?
	Patrick Ryan Philadelphia, USA	Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership
	Martijn Schuemie Rotterdam, NL	More Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership
	Morten Andersen Stockholm, Suède	How things happen in the Nordic countries?
	Darren Toh Boston, USA	Prospective surveillance of newly approved medical products
2013 edition
	Nancy Dreyer Boston, USA	Observational Studies of Effectiveness and Safety: Practical Applications and Challenges
	Ken Rothman Boston, USA	Ten Persistent Research Fallacies1. The randomized trial represents the perfect study design.2. Results from case-control studies are weaker than those from cohort studies, and the results from cohort studies are weaker than those from randomized trials.3. Study subjects should be representative of target populations.4. When measuring rates, the person-time of exposure to an agent goes in the denominator.5. The control group in ca-co studies should be just like the cases except that they don't have disease.
	Ken Rothman Boston, USA	Ten Persistent Research Fallacies (cont'd)6. When conducting multiple comparisons, take the number of comparisons into account when obtaining p-values.7. Account for missing data with an indicator term for "missingness" in a model8. A good way to categorize a variable is by quartiles or quintiles 9. A reasonable way to interpret data is by using significance tests10. Report power when reporting the results of a study.
	Samy Suissa Montreal, Canada	Time-related biases in pharmacoepidemiology: Randomized trials built on sand.
	Jacques Benichou Rouen	Attributable and competitive risks in pharmacoepidemiology
2011 edition
	Syd Shapiro† Capetown, South Africa	Oligognostic mega-analysis. Is Archie turning in his grave?
	Michal Abrahamowicz Montreal, Canada	Modeling the effects of time-varying drug exposures: alternative models, cumulative effects and further challenges
	Olaf Klungel Utrecht, The Netherlands	Improved control for confounding using propensityscores and instrumental variables
	Jeremy Rassen Boston, USA	Computational pharmacoepi - the frontier between computing and PE
	Tobias Kurth Paris/Bordeaux	The evaluation of different treatment effects in subgroups: practical uses of propensity scores
	Bernard Bégaud Bordeaux	« Who cares about The truth? Non-comparative comparisons are safer », the Guru says.
2010 edition
	Tom MacDonald Dundee, Scotland	A rant about everything that irritates me including data protection, privacy, consent, regulation and ethics, interspersed with singing, art, poetry, philosophy (home-spun and otherwise), fantasy worlds (where are we now) and perfect worlds (will we ever get there?) a bit about risks (to individuals) and benefits (to society), duty of care, politics, changing the world, how we and ISPE can do this and other random thoughts including expressing ideas that are not my own or new and more singing".
	Yola Moride Montreal – Canada	Why do I bother doing teleconferences in the middle of the night for data safety monitoring boards when nobody cares about denominators?
	Stephen Evans London UK	Pharmacoepidemiology and the pharmaceutical industry: undermined by their lawyers & tarnished by their funding?
	Judith K Jones Fairfax, Degge group, USA	The smorgasboard of exposure options- drugs, biologics, vaccines, devices --how long do you count the biological effect in a population study...?
	Miriam Sturkenboom Rotterdam, NL	The european database festival:one happy family?
	Alexander Walker Boston, USA	Signal Detection

Cookie	Type	Duration	Description
pll_language	persistent	11 months	This cookie is set by Polylang plugin for WordPress powered websites. The cookie stores the language code of the last browsed page.
viewed_cookie_policy	session	1h	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.